Sickle cell anemia is caused by a point mutation, the simplest type of genetic change possible. A single nucleotide in the HBB gene is swapped from A to T, which changes just one amino acid in the hemoglobin protein. That tiny alteration is enough to reshape red blood cells, shorten their lifespan, and cause a disease that affects an estimated 7.74 million people worldwide.
The Exact Mutation Behind Sickle Cell
The mutation sits in the HBB gene, which provides instructions for making the beta-globin chain of hemoglobin, the protein in red blood cells that carries oxygen. At position 6 on this chain, the amino acid glutamic acid is replaced with valine. Scientists write this as Glu6Val or E6V.
This is a missense point mutation, meaning a single DNA letter change produces a different amino acid rather than stopping protein production entirely. What makes this particular swap so damaging is the chemical difference between the two amino acids. Glutamic acid carries a negative electrical charge and interacts easily with water. Valine is hydrophobic, meaning it repels water and tends to stick to other hydrophobic surfaces. That one property change on the surface of the hemoglobin molecule is the root of everything that follows.
How One Amino Acid Reshapes a Blood Cell
Hemoglobin molecules carrying this valine substitution are called hemoglobin S (HbS), as opposed to the normal hemoglobin A (HbA). When HbS delivers oxygen to tissues and becomes deoxygenated, the exposed valine patch on one molecule locks onto a complementary pocket on a neighboring molecule. This triggers polymerization: HbS molecules stack into long, rigid fibers inside the red blood cell.
Those fibers distort the cell from its normal flexible disc shape into the stiff, crescent or “sickle” shape the disease is named for. Normal red blood cells live about 120 days. Sickle cells die in 10 to 20 days, which is why the body can’t keep up with replacing them, leading to chronic anemia. The rigid, sticky cells also get trapped in small blood vessels, blocking blood flow and causing episodes of intense pain known as vaso-occlusive crises. Over time, these blockages can damage organs that depend on steady blood supply.
Why It Takes Two Copies
Sickle cell anemia follows an autosomal recessive inheritance pattern. You need two copies of the mutated HBB gene, one from each parent, to develop the disease. People who inherit only one copy have what’s called sickle cell trait: they carry one gene for normal hemoglobin A and one for hemoglobin S. Carriers typically don’t experience symptoms because the normal hemoglobin in their red blood cells prevents widespread sickling.
When both parents carry the trait, each pregnancy has a 25% chance of producing a child with sickle cell disease, a 50% chance of producing a carrier, and a 25% chance of producing a child with two normal copies. Those odds reset with every pregnancy. A first child having the disease doesn’t change the probability for the next.
How Sickle Cell Is Diagnosed
In most of the United States and many other countries, newborns are screened for sickle cell disease at birth through a blood test. The key diagnostic tool is hemoglobin electrophoresis, which separates different types of hemoglobin by electrical charge. A person with sickle cell disease will show predominantly hemoglobin S rather than hemoglobin A. Newborns also have high levels of fetal hemoglobin (HbF), which is gradually replaced by either HbA or HbS during the first one to two years of life. This is why some symptoms of sickle cell disease don’t appear until after infancy, when fetal hemoglobin levels drop.
Why the Mutation Persists
A mutation this harmful might seem like it should disappear over generations, but sickle cell trait (carrying one copy) provides a survival advantage in regions where malaria is common. The parasite that causes malaria reproduces inside red blood cells, and cells with some hemoglobin S create a less hospitable environment for the parasite. This protective effect has kept the sickle cell gene at high frequency in populations from sub-Saharan Africa, the Mediterranean, the Middle East, and India, regions with a long history of malaria exposure.
Treatment Now Targets the Mutation Itself
For decades, treatment focused on managing symptoms: pain relief during crises, blood transfusions for severe anemia, and medications that boost fetal hemoglobin production to reduce sickling. A bone marrow transplant from a matched donor could cure the disease but carried significant risks and wasn’t available to most patients.
That changed in December 2023, when the FDA approved two gene therapies for sickle cell disease in patients 12 and older. One of them, Casgevy, is the first FDA-approved treatment using CRISPR gene-editing technology. Rather than fixing the HBB mutation directly, it edits a different gene to reactivate fetal hemoglobin production, which prevents red blood cells from sickling. The second, Lyfgenia, uses a viral delivery system to insert a modified gene that produces a form of hemoglobin designed to resist polymerization. Both require the patient’s own stem cells to be collected, edited in a lab, and infused back after chemotherapy clears the existing bone marrow.
These therapies represent the first time medicine can address the molecular cause of sickle cell disease rather than just its consequences. They are complex, expensive, and require weeks of hospitalization, but for patients with frequent pain crises, they offer the possibility of a functional cure rooted in correcting what a single DNA letter set in motion.